Plasminogen activator inhibitor-1 (PAI-1) activity post myocardial infarction: The role of acute phase reactants, insulin-like molecules and promoter (4G/5G) polymorphism in the PAI-1 gene

Atherosclerosis

Volumn 168, Issue 2, 2003, Pages 297-304

  Panahloo, Arshia ^a   Mohamed Ali, Vidya ^a   Gray, Rosaire P ^a   Humphries, Steve E ^a   Yudkin, John S ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cytokines; Myocardial infarction; PAI 1 gene; Plasminogen activator inhibitor 1 (PAI 1); Proinsulin like molecules

Indexed keywords

ACUTE PHASE PROTEIN; CYTOKINE; INSULIN; INSULIN LIKE MOLECULE; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DNA POLYMORPHISM; FEMALE; GENE DELETION; GENE INSERTION; GENOTYPE; HUMAN; INFLAMMATION; INSULIN LIKE ACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN FUNCTION; RISK FACTOR;

EID: 0037835451     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(03)00095-9     Document Type: Article

References (63)

1. Vague P., Juhan-Vague I., Aillaud M.F., et al. Correlations between blood fibrinolytic activity, plasminogen activator inhibitor levels, plasma insulin and relative body weight in normal and obese subjects. Metabolism. 35:1986;250-253.
2. Vague P., Juhan-Vague I., Chabert V., et al. Fat distribution and plasminogen activator inhibitor activity in non diabetic obese women. Metabolism. 38:1989;913-915.
3. Juhan-Vague I., Alessi M.C., Joly P., et al. Plasma plasminogen activator inhibitor-1 in angina pectoris influence of plasma insulin and acute-phase response. Arteriosclerosis. 9:1989;362-367.
4. Landin K., Tenborn L., Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J. Intern. Med. 227:1990;273-278.
5. Juhan-Vague I., Roul C., Alessi M.C., et al. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients - relationship with plasma insulin. Thromb. Haemost. 61:1989;370-373.
6. Almer L., Ohlin H. Elevated levels of the rapid inhibitor of plasminogen activator in acute myocardial infarction. Thromb. Res. 47:1987;335-339.
7. Gray R.P., Yudkin J.S., Patterson D.L. Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients. Br. Heart J. 69:1993;228-232.
8. Gray R.P., Yudkin J.S., Patterson D.L. Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor? Br. Heart J. 70:1993;530-536.
9. Sane D.C., Stump D.C., Topol E.J., et al. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. Thromb. Haemost. 65:1991;275-279.
10. Sinkovic A. Pretreatment plasminogen activator inhibitor-1 (PAI-1) levels and the outcome of thrombolysis with streptokinase in patients with acute myocardial infarction. Am. Heart J. 136:1998;406-411.
11. Hamsten A., De Faire U., Walldius G.M., et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 2:1987;3-9.
12. Mellbring G., Dahlgren S., Wiman B. Plasma fibrinolytic activity in patients undergoing major abdominal surgery. Acta Chir. Scand. 151:1985;109-112.
13. Kruithof E.K.O., Calandra T., Pralong G., et al. Evolution of plasminogen activator inhibitor type 1 in patients with septic shock- correlation with cytokine concentrations. Fibrinolysis. 7:1993;117-121.
14. Colucci M., Paramo J.A., Collen D. Generation in plasma of a fast acting inhibitor of plasminogen activator in response to endotoxin stimulation. J. Clin. Invest. 75:1985;818.
15. Emeis J.J., Kooistra T. Interleukin-1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J. Exp. Med. 163:1986;1260-1266.
16. Suffredini A.F., Harpel P.C., Parrillo J.E. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. New Engl. J. Med. 320:1989;1165-1168.
17. van Hinsbergh V.W.M., Kooistra T., van der Bergh E.A., et al. TNF increases the production of PAI in human endothelial cells in vitro and rats in vivo. Blood. 72:1988;1467-1470.
18. de Boer J.P., Abbink J.J., Brouwer M.C., et al. PAI-1 synthesis in the human hepatoma cell line Hep G2 is increased by cytokines - evidence that the liver contributes to the acute phase behaviour of PAI-1. Thromb. Haemost. 65:1991;181-185.
19. Woodhouse P.R., Meade T.W., Khaw K.T. Plasminogen activator inhibitor-1, the acute phase response and vitamin C. Atherosclerosis. 133:1997;71-76.
20. Neumann F.J., Ott I., Gawaz M., et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation. 92:1995;748-755.
21. Kanda T., Inoue M., Kotajima N., et al. Circulating interleukin-6 and interleukin-6 receptors in patients with acute and recent myocardial infarction. Cardiology. 93:2000;191-196.
22. Li D., Zhao L., Liu M., et al. Kinetics of tumor necrosis factor alpha in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor alpha in acute myocardial infarction. Am. Heart J. 137:1999;1145-1152.
23. Pannitteri G., Marino B., Campa P.P., et al. Interleukins 6 and 8 as mediators of acute phase response in acute myocardial infarction. Am. J. Cardiol. 80:1997;622-625.
24. Miyao Y., Yasue H., Ogawa H., et al. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am. Heart J. 126:1993;1299-1304.
25. Maury C.P.J., Teppo A.M. Circulating tumour necrosis factor-α (cachectin) in myocardial infarction. J. Intern. Med. 225:1989;333-336.
26. Smith S.J., Bos G., Esseveld M.R., et al. Acute-phase proteins from the liver and enzymes from myocardial infarction; a quantitative relationship. Clin. Chim. Acta. 81:1977;75-85.
27. Kunshner I., Gewurz H., Benson M.D. C-reactive protein and the acute phase response. J. Lab. Clin. Med. 97:1981;739-749.
28. Hirschl M.M., Gwechenberger M., Binder T., et al. Assessment of myocardial injury by serum tumour necrosis factor alpha measurements in acute myocardial infarction. Eur. Heart J. 17:1996;1852-1859.
29. Pietilä K.O., Harmoinen A.P., Jokiniitty J., et al. Serum C-reactive protein concentrations in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur. Heart J. 17:1996;1345-1349.
30. Thompson SG, Kienast J, Pyke SDM, et al. European concentrated action on thrombosis and disabilities angina pectoris study group. Haemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. New Engl. J. Med. 1995;332:635-41.
31. Liuzzo G., Biasucci L.M., Gallimore J.R. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. New Engl. J. Med. 331:1995;417-424.
32. Ridker P.M., Rifai N., Stampfer M.J., et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 101:2000;1767-1772.
33. Dawson S.J., Wiman B., Hamsten A. The two allele sequence of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene responds differently to IL-1 in HEPG2 cells. J. Biol. Chem. 268:1993;10739-10745.
34. Etude Cas Temoins de I'Infarctus du Mycocarde. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995;74:837-41.
35. Ossei-Gerning N., Mansfield M.W., Stickland M.H., et al. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler. Thromb. Vasc. Biol. 17:1997;33-37.
36. Panahloo A., Mohamed-Ali V., Lane A., Green F., Humphries S.E., Yudkin J.S. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes. 44:1995;37-42.
37. Eriksson P., Kallin B., van T., Hooft F.M., Båvenholm P., Hamsten A. Allele specific increase in basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction. Proc. Natl. Acad. Sci. USA. 92:1995;1851-1855.
38. WHO regional office for Europe. Public Health in Europe 5: Myocardial infarction Community Registers. Copenhagen, Annexe 1, 1976.
39. Mohamed-Ali V., Nagi D.K., Yudkin J.S. Simple, sensitive microplate IRMAs for intact and des 31,32 proinsulin compared with HPLC and cellulose IRMAs. Clin. Chem. 42:1996;977-979.
40. Juhan-Vague I., Alessi M.C., Raccah D., et al. Daytime fluctuations of plasminogen activator inhibitor 1 (PAI-1) in populations with high PAI-1 levels. Thromb. Haemost. 67:1992;76-82.
41. Andreotti F., Davies G.J., Hackett D.R., et al. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am. J. Cardiol. 62:1988;635-637.
42. Huber K., Rosc D., Resch I., Schuster E., Glogar D.H., Kaindl F., Binder B.R. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromb. Haemost. 60:1988;372-376.
43. Paganelli F., Alessi M.C., Morange P., Maixent J.M., Levy S., Juhan Vague I. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery. Thromb. Haemost. 82:1999;104-108.
44. Folsom A.R., Aleksic N., Park E., et al. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler. Thromb. Vasc. Biol. 21:2001;611-617.
45. Gray R.P., Panahloo A., Mohamed-Ali V., et al. Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction. Atherosclerosis. 130:1997;171-178.
46. Festa A., D'Agostino R. Jr, Mykkanen L. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler. Thromb. Vasc. Biol. 19:1999;562-568.
47. Kahn S.E., Halban P.A. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes. 46:1997;1725-1732.
48. Polonsky K.S., Gumbiner B., Ostrega D., et al. Alterations in immunoreactive proinsulin and insulin clearance induced by weight loss in NIDDM. Diabetes. 43:1994;871-877.
49. Nagi D.K., Hendra T.J., Ryle A.J., et al. The relationship of concentrations of insulin, intact proinsulin and 32,33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia. 33:1990;532-537.
50. Haffner S., Mykkänen L., Stern M.P., Valdez R.A., Heisserman J.A., Bowsher R.R. Relationship of proinsulin and insulin to cardiovascular risk factors in non diabetic subjects. Diabetes. 42:1993;1297-1302.
51. Båvenholm P., Proudler A., Silveira A., et al. Relationships of insulin and intact and split proinsulin to haemostatic function in young men with and without coronary artery disease. Thromb. Haemost. 73:1995;568-575.
52. Peavy D.E., Brunner M.R., Duckworth W.C., et al. Receptor binding and biological potency of several split forms (conversion intermediates) of human proinsulin: studies in cultured 1M-9 lymphocytes and in vivo and in vitro in rats. J. Biol. Chem. 260:1985;13989-13994.
53. Schneider D.J., Nordt T.K., Sobel B.E. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes. 41:1992;890-895.
54. Nordt T., Sawa H., Fujii S., et al. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation. 91:1995;764-770.
55. Nordt T.K., Sawa H., Fujii S., et al. Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo. J. Mol. Cell. Cardiol. 30:1998;1535-1543.
56. Jehle P.M., Lutz M.P., Fussgaenger R.D. High affinity binding sites for proinsulin in human IM-9 lymphoblasts. Diabetologia. 39:1996;421-432.
57. Dawson S., Hamsten A., Wiman B., et al. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasminogen activator inhibitor-1 activity. Arterioscler. Thromb. 11:1991;183-190.
58. Henry M., Tregouet D.A., Alessi M.C., et al. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. Arterioscler. Thromb. Vasc. Biol. 18:1998;84-91.
59. Ridker P.M., Hennekens C.H., Lindpaintner K., et al. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation. 95:1997;59-62.
60. Iacoviello L., Burzotta F., Di Castelnuovo A., et al. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb. Haemost. 80:1998;1029-1030.
61. Dangas G., Smith D.A., Unger A.H., et al. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb. Haemost. 83:2000;688-692.
62. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-5.
63. Wiesbauer F., Kaun C., Zorn G., Maurer G., Huber K., Wojta J. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br. J. Pharmacol. 135:2002;284-292.